New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:45 EDTPLXProtalix reported 2013 highlights
Protalix BioTherapeutics reported 2013 highlights. ELELYSO/UPLYSO highlights include: approval in Brazil, Mexico and Chile; in Israel, since the addition of ELELYSO to Israel's national healthcare reimbursement basket in early 2013, ELELYSO has become the drug of choice for naÔve adult Gaucher patients; in Chile, during the Q4 of 2013, all adult Gaucher patients previously treated with other enzyme replacement therapies were successfully switched to UPLYSO/ELELYSO; An application for a pediatric indication of ELELYSO has been submitted to the FDA. The Company also entered into a supply and technology transfer agreement in Brazil for UPLYSO, whereby Fiocruz committed to purchase at least approximately $40M worth of the drug during the first two years of the agreement and at least approximately $40M worth of the drug each subsequent year under the agreement. The first shipment of the drug to Brazil under the agreement with Fiocruz has just been made. The Company reported positive top-line phase I clinical trial results for Oral GCD in Gaucher patients.
News For PLX From The Last 14 Days
Check below for free stories on PLX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2014
13:48 EDTPLXProtalix to host conference call
Subscribe for More Information
August 28, 2014
13:17 EDTPLXPfizer, Protalix announce FDA approves ELELYSO pediatric indication
Subscribe for More Information
10:40 EDTPLXProtalix holder Bio-Cell in agreement to seek purchasers for 4.4M shares
Bio-Cell, a 10.7% stake holder in Protalix, announced that on August 13, Bio-Cell entered into an agreement with Barak Capital pursuant to which Barak will seek potential purchasers for 4,400,000 shares of Protalix Common Stock, following which Bio-Cell entered into agreements with a number of Israeli purchasers for the sale and purchase of said shares for a consideration of approximately $2.47 per share .Bio-Cell intends to use the consideration received by it pursuant the Transaction, to pay its expected tax liability to the Israeli Tax Authority in connection with Bio-Cellís proposed distribution of shares of Issuer's Common Stock, as a dividend to its shareholders on a pro rata basis.. Such expected tax liability was set forth in a pre-ruling delivered to Bio-Cell by the ITA. Bio-Cell expects that following the Dividend payment, it will no longer own any shares of Issuer's Common Stock. However, as of the date hereof, there is no certainty that the Dividend will be paid.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use